Online ISSN: 3007-0244,
Print ISSN:  2410-4280
EVALUATION OF THE EFFICACY 5-FLUOROURACIL ON ERECTILE FUNCTION IN PATIENTS UNDER SURGICAL TREATMENT OF BENIGN PROSTATE HYPERPLASIA
Introduction. The prevalence of erectile dysfunction in benign prostatic hyperplasia (BPH) is 5.2-40%. Urethral strictures as a complication of transurethral resection of the prostate is a risk factor for the development of postoperative erectile dysfunction. The purpose of the study is to evaluate the effectiveness of the prophylactic use of 5-fluorouracil in relation to erectile dysfunction in patients undergoing surgery for BPH. Materials and methods. The study included 246 patients who underwent surgery, with an average age of 70.0±8.0 years. The main group included 124 patients who, in addition to the standard postoperative treatment in the hospital, received prophylactic intervention after surgery in the form of washing with a solution of 5-fluorouracil using a modified three-way catheter. The control group consisted of 122 combined patients who underwent surgery for BPH and received standard postoperative treatment. To assess erectile dysfunction, the IIEF-5 questionnaire was used 3 and 6 months after surgery. All statistical analysis procedures were performed using the SPSS 20 program. For qualitative data, the significance of differences in groups was determined by calculating the Chi-square (χ2) test. For quantitative data, the result was expressed as the median and 25-75 percentiles. Calculations of the significance of differences were made using the Mann-Whitney test. Results. A statistically significant improvement in the erectile function of patients in both the main and control groups was established after surgery for 6 months (χ2 = 115.356; p < 0.001; χ2 = 115.034; p < 0.001, respectively). At the same time, in the main study group, the indicators had statistically significant differences with the control group. A twofold decrease in subjective symptoms of erectile dysfunction was shown in all patients, however, in the main study group, changes in these indicators were statistically significantly more pronounced (p=0.014 after 3 months; p=0.007 after six months). Conclusion. The high efficiency of the prophylactic use of 5-fluorouracil by irrigation of the bladder and urethra in relation to the erectile function of patients who underwent surgery for benign prostatic hyperplasia was established.
Yerbol М. Kairambayev1, https://orcid.org/0000-0002-1399-1451 Tolkyn А. Bulegenov1, https://orcid.org/0000-0001-6392-2748 Kuat D. Akimzhanov1, Muratkan Т. Kuderbayev1, Alexander I. Neimark2, Yerbol M. Smail1, https://orcid.org/0000-0003-3881-3747 Oxana A. Yurkovskaya1, https://orcid.org/0000-0002-4336-159X Zhanar М. Zhumanbayeva1, https://orcid.org/0000-0001-8941-862X Nataliya E. Glushkova3, https://orcid.org/0000-0003-1400-8436 1 NСJSC «Semey State Medical University», Semey, Republic of Kazakhstan; 2 Altay State Medical University, Barnaul, Russian Federation; 3 Al-Farabi Kazakh National University, Almaty, Republic of Kazakhstan.
1. Alexandrescu D., Fabi S., Yeh L.C., Fitzpatrick R.E., Goldman M.P. Comparative results in treatment of keloids with Intralesional 5- FU/Kenalog, 5-FU/Verapamil, Enalapril Alone, Verapamil Alone, and Laser: a case report and review of the literature // J Drug Dermatol. 2016. Vol. 15. Р.1442–1447. 2. Bapir R., Bhatti K.H., Eliwa A., García-Perdomo H.A., Gherabi N., Hennessey D., Magri V., Mourmouris P. et al. Effect of alpha-adrenoceptor antagonists on sexual function. A systematic review and meta-analysis // Arch Ital Urol Androl. 2022. Vol.94(2). Р.252-263. 3. Bijlard E., Steltenpool S., Niessen F.B. Intralesional 5- fluorouracil in keloid treatment: a systematic review // Acta Dermato-Venereol. 2015. Vol. 95. Р. 778–782. 4. European Association of Urology «Guidelines on Begin Prostatic Hyperplasia» Update March 2004 http://www. urotoday.com/images/stories/documents/prod/ (August, 2004). 5. Favorito L.A. Urethral stricture: the oldest urologic disease in 2017 // Int Braz J Urol. 2017. Vol.43(1). Р.1-2. 6. Hietanen K.E., Järvinen T.A., Huhtala H., Tolonen T.T., Kuokkanen H.O., Kaartinen I.S. Treatment of keloid scars with intralesional triamcinolone and 5-fluorouracil injections - a randomized controlled trial // J Plast Reconstr Aesthet Surg. 2019. Vol.72(1). Р. 4-11. 7. Jones M., Steggall M., Gelbart M. Catheterisation. Indwelling catheters in adults. City University, London 2012, 19 p. 8. Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary care setting // Can J Urol. 2012. Vol.19 (Suppl 1). Р.10–17. 9. King C., Rourke K.F. Urethral Stricture is Frequently a Morbid Condition: Incidence and Factors Associated With Complications Related to Urethral Stricture // Urology. 2019. Vol.132. Р.189-194. 10. Langan R.C. Benign Prostatic Hyperplasia // Prim Care. 2019. Vol.46(2). Р.223-232. 11. Lokeshwar S.D., Harper B.T., Webb E., Jordan A., Dykes T.A., et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia // Transl Androl Urol. 2019. Vol.8(5). Р.529-539. 12. McVary K.T. BPH: epidemiology and comorbidities // Am J Manag Care. 2006. Vol.12 (5 suppl): P.122–128. 13. McVary K.T., Roehrborn C.G., Avins A.L. Update on AUA guideline on the management of benign prostatic hyperplasia // J Urol. 2011. Vol.185(5). Р.1793–1803. 14. Montiel-Jarquín A.J., Gutiérrez-Quiroz C.T., Pérez-Vazquez A.L., Ortiz-Agustín J.J., Garcia-Galicia A., Loría-Castellanos J. Quality of life and erectile dysfunction in patients with benign prostatic hyperplasia // Cir Cir. 2021. Vol.89(2). Р. 218-222. 15. Oka A.A.G., Duarsa G.W.K., Novianti P.A., Mahadewa T.G.B., Ryalino C. The impact of prostate-transurethral resection on erectile dysfunction in benign prostatic hyperplasia // Res Rep Urol. 2019. Vol.11. Р.91-96. 16. Parsons J.K., Im R. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia // J Urol. 2009. Vol.182. Р.1463–1468. 17. Sangkum P., Levy J., Yafi F.A., Hellstrom W.J. Erectile dysfunction in urethral stricture and pelvic fracture urethral injury patients: diagnosis, treatment, and outcomes // Andrology. 2015. Vol.3(3). Р.443-449. 18. Sarma A.V., St Sauver J.L., Hollingsworth J.M. Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men // Urology. 2012. Vol.79. Р.102–108. 19. van Kollenburg R.A.A., de Bruin D.M., Wijkstra H. Validation of the Electronic Version of the International Index of Erectile Function (IIEF-5 and IIEF-15): A Crossover Study // J Med Internet Res. 2019. Vol.21(7). e13490. 20. Zhou W., Yu Q., Ma J., Xu C., Wu D., Li C. Triamcinolone acetonide combined with 5-fluorouracil suppresses urethral scar fibroblasts autophagy and fibrosis by increasing miR-192-5p expression // Am J Transl Res. 2021. Vol.13(6). Р.5956-5968.
Количество просмотров: 538

Ключевые слова:


Библиографическая ссылка

Kairambayev Ye.М., Bulegenov T.А., Akimzhanov K.D., Kuderbayev M.Т., Neimark A.I., Smail. Ye.M., Yurkovskaya O.A., Zhumanbayeva Zh.М., Glushkova N.E. Evaluation of the efficacy 5-fluorouracil on erectile function in patients under surgical treatment of benign prostate hyperplasia // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 2, pp. 105-110. doi 10.34689/SH.2023.25.2.015

Авторизируйтесь для отправки комментариев